Autologous BM-MNCs for Lower Extremity Compartment Syndrome

Phase 1, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in Compartment Syndrome (3 arms), sponsored by Oregon Health & Science University. Primary endpoints: Incidence of combined adverse events related to study agent intervention at 24 months and Efficacy as determined by muscle strength at 12 months. Started Dec 2019; status: active, not recruiting.